Vasilios Athans

[Vasilios Athans @AthansID]

This is great.

[Vasilios Athans @AthansID]

@keenanconazole @InYourFAECIUM @julie_justo @BBookstaver_USC I was told it was a manufacturing issue (rubber vial stoppers). Original outage was supposed to be through late November but it got pushed back to mid/late December now

[Nick Mercuro @n_mercuro]

It was an incredible experience collaborating with leaders at @HenryFordHealth to implement Rx-driven antimicrobial stewardship services during transitions of care @idpharmprof @rkenneypharmd @cmedler35 @nancymacpharmd @mahREElen @ErikssonErin @BeaulacAmy
https://t.co/gDVzQk5HQH

[Vasilios Athans @AthansID]

@MK_IDpharm @SIDPharm @accpinfdprn Ours have been mostly or entirely through Penn Home Infusion. They cover most of NJ/DE/Western PA territory-wise, so your patients may qualify depending on insurance and zip code, etc!

[SIDP @SIDPharm]

SIDP has a great research mini series for those interested https://t.co/RlzyJpmCVT #RxResiChat

[SIDP @SIDPharm]

🆕Do you have the biomarker blues?

Faculty @DiariPharmd + Carla Walraven discuss the utility of fungal biomarkers for the dx of candidiasis among ⬆️-risk ICU patients in our latest SIDP Journal Club Series (https://t.co/gTtPZxZWAq) worth 1.5h #ACPE #BCIDP credit!
#IDTwitter

[Vasilios Athans @AthansID]

@HFHInfDisFellow Bifidobacterium

[SIDP @SIDPharm]

Does pip-tazo stack up against meropenem for Gram(-) bacteremia? The debate continues w/ MERINO-2, which evaluates treatment of SPICE bugs. Join faculty @GramPosiTiff & @domkchan in our latest SIDP Journal Club Series (https://t.co/gTtPZxZWAq), worth 1.5h of #ACPE #BCIDP credit!

[Camille Nelson Kotton @KottonNelson]

Exciting news, a new treatment is FDA approved for resistant refractory CMV! Takeda’s LIVTENCITY (maribavir) For People 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Wo Genotypic Resistance) to Conventional Antiviral Therapy https://t.co/LfLjQffiHe

[Aaron Richterman, MD @AaronRichterman]

Please share widely / RT:

Penn Summer Program in Infectious Diseases Research (SPIDR) app is live! This is a paid, mentored summer research program for underrepresented in medicine trainees from HS to med school. https://t.co/vgPvj4uGcV
@KreiderTed @EmilyBlumbergMD

[Mark Gilchrist @MGilchrist123]

Another 👍🏻 output from ⁦@eopat⁩ ⁦@BSACandJAC⁩ & our drug stability prog - Assessment of ceftolozane/tazobactam stability in opat. We look forward to more agents coming through! ⁦@jamiesonce⁩ ⁦@raseaton66⁩ ⁦⁦@doctorsanjay⁩ https://t.co/qVeTEjQFOA

[Vasilios Athans @AthansID]

@Cortes_Penfield IV only for osteo, overestimation of linezolid/serotonin syndrome risk, and needing to start dual antifungals routinely as a bridge until therapeutic azole concentration confirmed

[SIDP @SIDPharm]

Can we safely put a PAUSE on antibiotic prescribing for RTI? In the latest SIDP Journal Club Series release (https://t.co/gTtPZxZWAq), @KP_IDPHARM reviews a recent meta-analysis evaluating delayed abx prescribing vs immediate/no abx. Available for 1.5 hours of ACPE/BCIDP credit!

[Paul Sax @PaulSaxMD]

Anyone who does inpatient ID and tries to set up home IV antibiotic therapy will instantly recognize why daptomycin is far superior to vanco for patient satisfaction -- ESPECIALLY with vanco q8 hours. That's some kind of torture
https://t.co/FL614DBxpk @mmPharmD

[SIDP @SIDPharm]

🚨RPDs🚨

Get your residents started on the path to research success w/ the #SIDPResearchMiniSeries! Be ready for #practicebasedresearch during residency & beyond. (P.S. - It’s great for new practitioners too!)

Access here: https://t.co/59NKZwB3ET or https://t.co/6uZHMmJTcs

[Erin McCreary @ErinMcCreary]

woohoo, out today! listen to this group of super smart, wonderful humans talk all things PK/PD, beta lactam exposures and targets, & TDM!

https://t.co/jcFAmvvLq9

(minor audio glitch this AM so if you listened to a different episode, you can go back now for even more content!)

[SIDP @SIDPharm]

Are you #deranged....in your beta-lactam dose/exposures? If so, check out our newest #Breakpoints episode as @Veena_PharmD, Joseph Kuti, @jasonroberts_pk, & @IDPharmacometrx join @ErinMcCreary to discuss #TDM of beta-lactams!

https://t.co/2FLKucM9eR

#Thelevelisinthedetails 😈

[Ben @be_nMD]

Half of medicine is people getting better on their own but thinking you did something

[SIDP @SIDPharm]

In need of more #BCIDP credits??

Take a look at this #enduringwebinar from @DS_Burgess on MDROs including #MRSA, #VRE, #ESBLs, #CRE, #CRAB and more! 🦠

Find it here: https://t.co/59NKZwjsgj

[TransplantID Journal @TheTxIDjournal]

Impt new📜by @klindermycin @dan_dkauld
Multicenter cohort of transplant pts with refractory, resistant or intolerance to standard CMV Rx, given Letermovir as treatment. Outcomes best if VL <1000 IU, if over 1000 IU - use with caution #TxID #CMV https://t.co/M79oLD3ypE